Why Novavax Was a Coronavirus Stock Winner After Hours Today | The Motley Fool
Coronavirus vaccine developer Novavax‘s (NASDAQ:NVAX) stock blasted more than 30% higher in after-market trading on Thursday in reaction to good news about its vaccine candidate.
Novavax announced after market hours that its NVx-CoV2373 met its primary endpoint and demonstrated over 89% efficacy in a phase 3 clinical trial in the U.K. Severe, serious, and medically attended adverse events were at low levels.
The biotech also reported encouraging results for a phase 2b study undertaken in South Africa, although the efficacy was lower (60% in the case of HIV-negative participants, who comprised 94% of the study).
Crucially, “NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but…